Who understands drug pricing?; Walgreens eyes more tie-ups with pharma; Biogen, SOBI roll out Elocta in Europe;

@FiercePharma: Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Waiting for flight/playing "guess where these guys work based on overheard description of latest clinical trial failure." | Follow @CarlyHFierce

> The complex--and often secret--nature of drug pricing in the U.S. has complicated public debate about the issue. Report

> Walgreens ($WBA) says it's looking at follow-up specialty pharmacy deals with drugmakers now that it has sealed a pact with troubled Valeant Pharmaceuticals ($VRX) on a slate of meds. Report

> Swedish Orphan Biovitrum said Elocta, a long-acting hemophilia A treatment it developed with Biogen ($BIIB), has been launched in Europe. Release

> SkyePharma said it expects to beat its 2015 forecast thanks to a sales-related milestone payment from its partner on the respiratory med flutiform, Mundipharma. Report

> Valneva said its Japanese encephalitis vaccine won approval in Taiwan through its partner there, Adimmune. Report

Medical Device News

@FierceMedDev: ICYMI: Israeli startup raises $10M to back transcatheter aortic valve stenosis treatment. Article | Follow @FierceMedDev

@EmilyWFierce: Who's on board with Twitter's 10,000 character limit? Pharma brand managers. FiercePharmaMarketing story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Startup raises $14M to commercialize its filter to prevent blood clots during hospitalization. Article | Follow @VarunSaxena2

> Illumina focuses on 'holy grail market opportunity' with liquid biopsy spinoff. Article

> Thermo Fisher to buy Affymetrix for $1.3B to beef up in genetic analysis. Report

> JPM: Med tech 'innovation studio' debuts thanks to $15M investment from American Medical Association. Story

Biotech News

@FierceBiotech: The Bradner factor: Roche bags a BET inhibitor in $535M Tensha buyout. Article | Follow @FierceBiotech

@JohnCFierce: Shire finally gets it done, bagging Baxalta in $32B buyout. News | Follow @JohnCFierce

> Accelerator's second NYC biotech startup sets out with $17M and some Gates-backed science. Story

> Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma. More

> Landmark $1.9B-plus deal for Seres includes PhIII support. Article

Animal Health News

> USDA shifts attention to diagnostics to curb deadly pig virus. More

> China Animal Healthcare creates embarrassment for stakeholder Lilly. Report

> Startup AGL launches dog-collar sensor for remote tracking of chronic illnesses. Story

> Researchers ID link between fish-flavored cat food and thyroid disease. Item

> Zoetis offloads manufacturing sites as CFO embraces activist investors. Article

Biotech IT News

> Roche leads $175M investment in oncology software player Flatiron. News

> MC10 pitches data-gathering wearable patch at research community. Report

> Pfizer taps Adaptive to add NGS, bioinformatics skills to immuno-oncology drive. Story

> Michael J. Fox Foundation signs up for wearable-enabled Phase III trial project. Item

> Vertex inks deal to add Genomics' database, algorithms to drug discovery toolkit. Article

Pharma Marketing News

> Who's on board with Twitter's 10,000 character limit? Pharma brand managers. Story

> Will GSK's no-speaker-fee system work? Execs say yes; critics, not so much. More

> Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. Article

> Shire to take on hemophilia marketing with long-sought Baxalta buy. Item

And Finally... A large new study, published in the BMJ, found no risk of birth defects from oral contraceptives. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.